Medical College of Wisconsin
CTSIResearch InformaticsREDCap

Reassessing the Duration of Induction Therapy for Newly Diagnosed, Transplant-Eligible Myeloma Patients in the Context of Quadruple CD38 Monoclonal Antibody-Based Regimens: Is 24 Weeks Optimal? Am J Hematol 2026 May;101(5):1141-1147

Date

01/27/2026

Pubmed ID

41588844

DOI

10.1002/ajh.70215

Scopus ID

2-s2.0-105029059723 (requires institutional sign-in at Scopus site)

Author List

Mohan M, Radhakrishnan S, Schinke C, Katodritou E, Fonseca R

Author

Sabarinath Venniyil Radhakrishnan MD Assistant Professor in the Medicine department at Medical College of Wisconsin